XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2

Segment Reporting (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) business	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) reportablesegments business	Sep. 30, 2021 USD ($)
Segment Reporting [Abstract]
Number Of Businesses | business	5		5
Number of reportable segments | reportablesegments			2
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Amortization expense	$ (202)	$ (184)	$ (604)	$ (549)
Operating income (loss)	358	387	1,247	1,019
Other expense, net	(114)	95	(502)	(62)
Income (loss) before income taxes	245	483	745	957
Impact of Foreign Currency Fluctuations on Net Sales	(155)	8	(294)	65
Net sales	3,170	2,932	9,440	8,761
United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	1,934	1,726	5,645	5,112
International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	1,236	1,206	3,795	3,649
Endoscopy [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	559	533	1,649	1,583
Endoscopy [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	342	306	992	902
Endoscopy [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	217	227	657	681
Urology and Pelvic Health [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	433	384	1,296	1,142
Urology and Pelvic Health [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	315	275	921	817
Urology and Pelvic Health [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	118	109	375	325
Neuromodulation [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	221	221	669	666
Neuromodulation [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	173	175	519	520
Neuromodulation [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	48	46	150	145
Interventional Cardiology Therapies
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	549	534	1,667	1,634
Interventional Cardiology Therapies | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	190	193	568	593
Interventional Cardiology Therapies | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	359	341	1,099	1,041
Watchman
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	262	210	738	596
Watchman | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	234	183	662	524
Watchman | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	28	26	76	72
Cardiac Rhythm Management [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	519	512	1,580	1,505
Cardiac Rhythm Management [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	338	312	1,005	903
Cardiac Rhythm Management [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	181	199	575	603
Electrophysiology [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	148	86	418	265
Electrophysiology [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	73	32	196	96
Electrophysiology [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	75	55	222	169
Cardiology [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	1,479	1,342	4,403	4,000
Cardiology [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	836	720	2,431	2,115
Cardiology [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	643	622	1,972	1,885
Peripheral Interventions [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	479	452	1,423	1,358
Peripheral Interventions [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	269	250	782	748
Peripheral Interventions [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	210	202	641	609
Specialty Pharmaceuticals [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Revenues from contracts with customers, disaggregated - performance measurement	0	0	0	13
Net sales	0	0	0	13
Specialty Pharmaceuticals [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	0	0	0	10
Specialty Pharmaceuticals [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	0	0	0	4
MedSurg [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Operating Income Allocated to Reportable Segments	399	370	1,168	1,117
Revenues from contracts with customers, disaggregated - performance measurement	$ 1,260	$ 1,135	$ 3,702	$ 3,368
Segment operating income as percentage of net sales	31.70%	32.60%	31.60%	33.20%
Net sales	$ 1,213	$ 1,138	$ 3,614	$ 3,390
MedSurg [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	830	756	2,432	2,239
MedSurg [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	383	382	1,182	1,151
Cardiovascular [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Operating Income Allocated to Reportable Segments	542	479	1,562	1,468
Revenues from contracts with customers, disaggregated - performance measurement	$ 2,065	$ 1,789	$ 6,032	$ 5,315
Segment operating income as percentage of net sales	26.30%	26.80%	25.90%	27.60%
Net sales	$ 1,958	$ 1,794	$ 5,826	$ 5,358
Cardiovascular [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	1,104	970	3,213	2,864
Cardiovascular [Member] | International [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	853	824	2,613	2,494
BSX Reportable Segments [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Revenues from contracts with customers, disaggregated - performance measurement	3,325	2,924	9,734	8,683
Net sales	3,170	2,932	9,440	8,748
BSX Reportable Segments [Member] | United States
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Net sales	1,934	1,726	5,645	5,103
Total allocated to reportable segments [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Operating income (loss)	942	849	2,730	2,585
Specialty Pharmaceuticals [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Operating income (loss)	0	0	0	4
Corporate expenses and currency exchange [Member]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Operating Income Unallocated to Segment	(132)	(99)	(321)	(397)
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Operating Income Unallocated to Segment	$ (249)	$ (178)	$ (558)	$ (624)

X

- Definition

Impact of Foreign Currency Fluctuations on Net Sales

+ References

No definition available.

+ Details

Name:	bsx_ImpactOfForeignCurrencyFluctuationsOnNetSales
Namespace Prefix:	bsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number Of Businesses

+ References

No definition available.

+ Details

Name:	bsx_NumberOfBusinesses
Namespace Prefix:	bsx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Operating Income Allocated to Reportable Segments

+ References

No definition available.

+ Details

Name:	bsx_OperatingIncomeAllocatedToReportableSegments
Namespace Prefix:	bsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Operating Income Unallocated to Segment

+ References

No definition available.

+ Details

Name:	bsx_OperatingIncomeUnallocatedToSegment
Namespace Prefix:	bsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenues from contracts with customers, disaggregated - performance measurement - measures used by CODM to make business decisions, excludes impact of foreign currency fluctuations

+ References

No definition available.

+ Details

Name:	bsx_RevenuesFromContractsWithCustomersDisaggregatedPerformanceMeasurement
Namespace Prefix:	bsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Segment operating income as percentage of net sales

+ References

No definition available.

+ Details

Name:	bsx_Segmentoperatingincomeaspercentageofnetsales
Namespace Prefix:	bsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Name:	us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_NonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599

+ Details

Name:	us-gaap_NumberOfReportableSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_WatchmanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bsx_SpecialtyPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_BSXReportableSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_TotalAllocatedToReportableSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialtyPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_CorporateExpensesincludinghedgingactivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bsx_SpecialChargesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: